# A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors

> **NCT04615312** · PHASE1 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Digestive System Tumors

## Interventions

- **DRUG:** a CDK4 / 6 inhibitor and a MEK inhibitor

## Key facts

- **NCT ID:** NCT04615312
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-14
- **Primary completion:** 2021-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04615312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04615312, "A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04615312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*